The START Center - San Antonio
South Texas Accelerated Research Therapeutics
San Antonio, TX
Accepting patients
QXL138AM
A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
- Masked Immunocytokine (MIC)
- CD138
- Phase 1